# Globe Life (GL)

Sector: Life and health insurance

| Field | Value |
|---|---|
| Price | $151.66 |
| Market cap | $11B |
| Intrinsic value source | AI estimate |
| Data as of | 2026-11-20 |
| Next earnings | 2027-01-21 (estimate) |

Analysts: Leaning bullish

Picks: Research only

Discount category: Below intrinsic value

## In short

The market doubts Globe Life after the short seller reports, the class action and new health losses at United American, and 2027 earnings within its guidance with lower health losses can lift its value.

## Themes and gap

- Themes: Regulation and courts (regulation-legal), Weak consumer (weak-consumer)
- Gap type: Can close (closable)
- Why: The Q4 2026 results and 2027 results show if losses at United American stop and if Globe Life meets its 2027 guidance, and the class action can end with a ruling or a settlement.

## About

Globe Life Inc. (GL) sells basic life insurance and supplemental health insurance to middle-income families in the United States. It sells through exclusive agencies: American Income Life, which focuses on union and credit union members, Liberty National and Family Heritage. It also sells directly to consumers by mail, phone and online, and through the independent United American agency, which sells Medicare Supplement and, through Evry Health, group health insurance. Life insurance was 66% of premium revenue and 80% of the insurance underwriting margin in Q3 2026. Total premium was $3.88 billion in the first nine months of 2026. Globe Life reports in US dollars, and its shares trade on the NYSE.

## Thesis

The market prices Globe Life with doubt since April 2024, when short seller reports made claims about the practices of its agencies. A securities class action and several shareholder derivative suits, which come in part from those reports, are still open, and the plaintiffs moved for class certification in May 2026. In Q3 2026, losses at Evry Health and a claims processing delay at the Centers for Medicare and Medicaid Services also caused an underwriting loss at United American, and Globe Life cut its 2026 guidance. The AI estimate uses a multiple of the 2027 net operating income per share that the company guides to. For the price to rise, three things must be true. Globe Life must earn 2027 net operating income per share within its guidance of $16.10 to $17.10. United American must return to an underwriting profit as Evry raises prices and selects risks more carefully. The class action and the derivative suits must end without a large payment. The Q4 2026 results, expected about January 21, 2027, are the next test, and the 2027 results show the trend over the next four quarters. If health losses grow, agent counts fall or a court rules against the company, the price can fall.

## Checkpoints

- Jan 21, 2027 (estimate): Q4 2026 results: health margins and 2026 earnings. Status: Pending. Watch: Net operating income for 2026 is within $15.35 to $15.65 per share and United American has an underwriting profit in Q4 2026, and this passes; a lower result or another underwriting loss fails.
- 2027 (estimate): Securities class action. Status: Pending. Watch: The court denies class certification or the case ends without a material payment, and this passes; class certification or a large settlement fails.

## Valuation

The intrinsic value for Globe Life is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Globe Life. The method is a multiple of net operating income per diluted share for 2027. Net operating income is the company's own measure. It leaves out realized investment gains and losses, legal proceedings and some other items, and it is after interest, stock compensation and tax. The Q3 2026 results (Form 8-K of October 21, 2026) give net operating income of $4.84 per diluted share for Q3 2026, which includes a gain of $120.5 million before tax from the annual update of reserve assumptions. The Q1 and Q2 2026 results give $3.43 and $3.61 per share, so the first nine months were $11.88 per share. The Q3 2026 results give 2026 guidance of $15.35 to $15.65 per share and 2027 guidance of $16.10 to $17.10 per share. They also give book value per share without accumulated other comprehensive income of $103.62 at September 30, 2026. Because net operating income is after interest, the estimate makes no separate debt adjustment. The Form 10-Q gives debt with a par value of $3,019 million at September 30, 2026. The cover of the Form 10-Q gives 75,439,736 shares of common stock at October 30, 2026, and the estimate uses the per diluted share figures of the company. The 2027 net operating income per share and the multiples are assumptions. The low case assumes $15.60 per share, below the guidance, because losses at United American continue and lapses rise, at 8 times. It gives $124.80 per share. The base case assumes $16.50, near the middle of the guidance, at 10.5 times. It gives $173.25 per share. The high case assumes $17.10, the top of the guidance, at 12 times. It gives $205.20 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $169.13 per share. Globe Life sells small basic life and supplemental health policies to middle-income families through its own exclusive agencies and by direct mail and online. Its life underwriting margin was 53% of premium in Q3 2026, and the company has kept high margins for many years. Its agency systems are costly to build, and its policies stay in force for many years. These give an advantage that can last 10 years or more. But other insurers can sell similar policies, and the company must recruit new agents all the time. The estimate uses no results after September 30, 2026.

As of 2026-11-14.

Sources:

- https://www.sec.gov/Archives/edgar/data/320335/000032033526000224/q3fy2026earningsrelease.htm
- https://www.sec.gov/Archives/edgar/data/320335/000032033526000231/gl-20260930.htm

## Balance sheet

- Cash: $353M
- Debt: $3.0B
- Net debt: $2.7B
- Debt due within 12 months: $319M
- Last debt due: 2061

At September 30, 2026, Globe Life had cash and short-term investments of $353 million and total debt with a par value of $3,019 million. Long-term debt was $2,700 million: senior notes due 2028 to 2034, junior subordinated debentures due 2057 and 2061, and a $450 million term loan due 2029. Short-term debt was $309 million of commercial paper and $10 million of Federal Home Loan Bank borrowings. The $1 billion credit facility, which backs the commercial paper, matures in June 2031 and was not drawn. Globe Life also has a $500 million pre-capitalized trust securities facility that lets it issue senior notes when it chooses. Shareholders' equity was $6,618 million, or $8,035 million without accumulated other comprehensive income. The insurance subsidiaries had $19.6 billion of investments, of which 86% were fixed maturities, and 97% of fixed maturities were investment grade.

As of 2026-09-30.

Sources:

- https://www.sec.gov/Archives/edgar/data/320335/000032033526000231/gl-20260930.htm
- https://www.sec.gov/Archives/edgar/data/320335/000032033526000224/q3fy2026earningsrelease.htm

## Dividends

- Dividend yield: 0.8% (last 12 months, at the current price)
- Paid per share, last 12 months: $1.26 (4 payments)
- Current annual rate: $1.32 ($0.33 x 4 a year)
- Payout ratio: 7% of the earnings of the last fiscal year (the year ended 2025-12-31)
- Latest ex-dividend date: 2026-10-05, $0.33 per share
- Growth from 2020 to 2025: 7.3% a year
- Growth from 2016 to 2025: 7.3% a year

Dividends per share by year: 2016: $0.555, 2017: $0.59, 2018: $0.63, 2019: $0.679, 2020: $0.737, 2021: $0.782, 2022: $0.822, 2023: $0.883, 2024: $0.945, 2025: $1.05.

Source: company filings and market data, read on 2026-11-13.

## Recent events

- 2026-11-04: The Board adopted amended by-laws. The lead independent director can now call special meetings of the Board, and the Compensation Committee now sets the pay only of executive officers.
- 2026-10-21: Globe Life reported Q3 2026 results. Net operating income was $4.84 per diluted share, against $4.81 a year earlier, and total premium grew 7%. United American had an underwriting loss because of high-severity claims at Evry and a claims processing delay at the Centers for Medicare and Medicaid Services. Globe Life lowered its 2026 guidance to $15.35 to $15.65 per share and gave 2027 guidance of $16.10 to $17.10 per share.
- 2026-08-06: Globe Life raised its quarterly dividend by 22% to $0.33 per share, and the Board authorized up to $2.5 billion under the share repurchase program.
- 2026-07-22: Globe Life reported Q2 2026 results. Net operating income was $3.61 per diluted share, 10% more than a year earlier, and it raised its 2026 guidance to $15.55 to $15.95 per share.
- 2026-06-26: Globe Life amended its $1 billion credit facility, which now matures in 2031, and increased its term loan from $250 million to $450 million, with maturity extended to June 2029.
- 2026-04-22: Globe Life reported Q1 2026 results. Net operating income was $3.43 per diluted share, 12% more than a year earlier, and it raised its 2026 guidance to $15.40 to $15.90 per share.
- 2026-02-04: Globe Life reported 2025 results. Net operating income was $14.52 per diluted share, against $12.37 in 2024.

## Latest news and filings

- Last earnings: 2026-10-21 (8-K: https://www.sec.gov/Archives/edgar/data/320335/000032033526000224/)
- Next earnings: 2027-01-21 (expected; the company has not confirmed it)

| Filed | Form | Headline | Period end | XBRL document | Link |
| --- | --- | --- | --- | --- | --- |
| 2026-11-05 | 8-K | Change to shareholder rights or bylaws |  | gl-20261105 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000233/gl-20261105.htm |
| 2026-11-04 | 10-Q | Quarterly report for the period ended Sep 30, 2026 | 2026-09-30 | gl-20260930 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000231/gl-20260930.htm |
| 2026-10-21 | 8-K | Earnings release |  | gl-20261021 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000224/ |
| 2026-08-07 | 8-K | Change of directors or officers |  | gl-20260807 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000218/gl-20260807.htm |
| 2026-08-05 | 10-Q | Quarterly report for the period ended Jun 30, 2026 | 2026-06-30 | gl-20260630 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000216/gl-20260630.htm |
| 2026-07-22 | 8-K | Earnings release |  | gl-20260722 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000203/ |
| 2026-06-29 | 8-K | New material agreement |  | gl-20260629 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000198/gl-20260629.htm |
| 2026-05-07 | 10-Q | Quarterly report for the period ended Mar 31, 2026 | 2026-03-31 | gl-20260331 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000169/gl-20260331.htm |
| 2026-05-04 | 8-K | Change of directors or officers and Shareholder vote results |  | gl-20260504 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000160/gl-20260504.htm |
| 2026-04-22 | 8-K | Earnings release |  | gl-20260422 | https://www.sec.gov/Archives/edgar/data/320335/000032033526000143/ |

Every filing on SEC EDGAR (CIK 320335): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000320335&type=&dateb=&owner=include&count=40

## Risks

- High: A securities class action for the period from May 2019 to April 2024 and several shareholder derivative suits are open. They come in part from short seller reports about the agencies. The plaintiffs moved for class certification in May 2026, and the company cannot estimate the amount of a loss.
- Medium: Evry Health, a young group health business, caused an underwriting loss of $26 million in the first nine months of 2026, and its results can stay volatile while it grows.
- Medium: Growth depends on the number of agents. The average producing agent count at American Income fell 7% in Q3 2026 from a year earlier.
- Medium: Medicare Supplement claims and medical cost trends are rising, and the company needs regulators to approve premium rate increases on health policies.
- Low: Changes in interest rates move the fair value of the bond portfolio, which had a net unrealized loss of $2,687 million at September 30, 2026, and change the yield on new investments.

## Links

- Page: https://picks.utilarium.app/company/GL/
- History of changes: https://picks.utilarium.app/company/GL/history/
- JSON with full history: https://picks.utilarium.app/data/company/GL.json

> Picks is a personal record of stock picks. It gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Prices, intrinsic values and ratings can be delayed or wrong; check the original source. Full disclaimer: /disclaimer/.
